Continuation of Drug Supply in Chinese Patients After CAMN107DBR01 study Termination
Phase of Trial: Phase IV
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Expanded access
- Sponsors Novartis Pharmaceuticals
- 12 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 Mar 2013 New trial record